The FDA recently advised caution in the use of compounded ketamine preparations which can be obtained via telemedicine platforms, as they are not subject to the same checks and balances as FDA-approved versions which require patient observation by a healthcare provider for a number of hours after administration. There are concerns about the risk of respiratory depression, sedation, and dissociation amongst others. There is only an esketamine formulation that is currently FDA-approved for psychiatric indications, no ketamine products are approved yet for psychiatric indications.

Read the FDA advisory here.